Session Abstract – PMWC 2022 Silicon Valley


The PMWC 2022 Genomic Profiling Showcase will provide a 15 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.


Confirmed Presenting Companies:

 Session Chair Profile

M.D., Chief Medical Officer, Agendia

Biography
Dr. William Audeh is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles, where he continues to be a member of the Medical Staff. He became Chief Medical Officer of Agendia, a molecular diagnostics company specializing in breast cancer genomics, in May of 2016. Prior to joining Agendia, in addition to his clinical practice, he served as Director of the Cedars-Sinai Cancer Center, Clinical Chief of the Division of Hematology/Oncology, and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh was also a faculty member in the Breast Surgery and Surgical Oncology Fellowships at Cedars-Sinai and was Associate Clinical Professor of Medicine at the UCLA School of Medicine. Dr Audeh obtained his MD degree for the University of Iowa, MS in Genetics from University of Minnesota, and Internal Medicine and Oncology training at Stanford University.


Genomic Profiling Showcase:
Agendia

From day one, Agendia was founded on the belief we could improve the quality of life for cancer patients everywhere. Today, our genomic tests are achieving this goal with a broad and growing global customer base, including many major hospitals and clinical institutions.

 Session Chair Profile

Chief Operating Officer, Pacific Biosciences

Biography
Mark recently joined PacBio where he will manage our research, development and manufacturing organizations and will be responsible for driving our strategic planning and corporate development activities. Mark joins the company from Illumina, Inc. where he most recently served as Senior Vice President and Chief Commercial Officer. In that role, he was responsible for the development and implementation of lllumina’s commercial strategy and oversaw worldwide sales and services of over $3B in annual revenue and ~1,800 commercial employees. Prior to Illumina, Mark was the Director of Genotyping Services for Ellipsis Biotherapeutics. He earned as B.S. in Biochemistry from Western University and was a Ph.D. candidate at the University of Toronto in the department of Molecular and Medical Genetics. During that time, his research was focused on Cystic Fibrosis at the Hospital for Sick Children in Toronto.


Genomic Profiling Showcase:
Pacific Biosciences

PacBio Systems are powered by Single Molecule, Real-Time Sequencing and provide comprehensive views of genomes, transcriptomes, and epigenomes. As the only sequencing technology to offer highly accurate long reads (HiFi reads), PacBio provides unparalleled access to the full spectrum of genetic variation in any organism

 Speaker Profile

CEO, Scipher Medicine

Biography
Alif is a pioneer in integrating network science with molecular data to match individual patients with the most effective therapies. Alif and his team have spent the last decade pioneering a network medicine platform – a powerful tool that has the potential to predict patient response to targeted therapies, develop precision diagnostics and repurpose previously approved drugs. A Swedish national with a perspective on global healthcare systems, Alif has led cross-disciplinary teams throughout Asia, Europe, and the Americas - raising over $225M in venture and private equity capital. Alif is an experienced speaker and writer on healthcare topics and was recently featured on The Bio Report podcast (“Bringing Precision Medicine to Autoimmune Disease”), at the BIO International Convention (“Precision Medicine Outside Oncology: One Size Does Not Fit All),” and on Morning Consult (“Addressing Healthcare’s Largest Hidden Cost: Drug Nonresponse”).


Genomic Profiling Showcase:
Scipher Medicine

Scipher Medicine is committed to transforming the way healthcare prioritizes drugs for patients. Our first product, PrismRA, is a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to the world's best-selling drug class: TNF inhibitors.

Bringing Precision Medicine To Autoimmune Disease
In rheumatoid arthritis, only 1 in 3 patients respond to the top biologic therapies. Scipher Medicine’s PrismRA test identifies patients who are less likely to respond to TNFi therapies, allowing patients to optimize drug class selection prior to treatment.

 Speaker Profile

Ph.D., CEO, Ciscovery Bio

Biography
Before founding Ciscovery Bio, Dr. Joonyul Kim had managed Proximity Biosciences as the founder CEO for 5 yrs. While at the company, he received multiple federal/state fundings including NSF STTR Phase I, and made research contracts with drug discovery companies.


Genomic Profiling Showcase:
Ciscovery Bio

Ciscovery Bio is a non-coding biomarker company that discovers and utilizes cis-regulatory modules for drug development and treatment.

Cis-regulatory Modules as Non-coding Biomarkers
Cis-regulatory modules (CRMs) are highly sensitive sensors for drug-induced cellular changes and strong candidates for precision medicine, but most of them still remain unexplored. Our genome-scale CRM discovery tool enabled more than 100,000 functionally-validated CRMs for profiling drugs and for searching the variants.

 Speaker Profile

Ph.D., M.D., Chief Medical Officer, Beverly Hills Institute for Precision Medicine

Biography
Dr. Stanford’s clinical practice is focused on providing consultative services to primary care providers for the purposes of the integration of precision medicine into primary care plans. This approach is novel from its comprehensive nature and practical real-world implementation. Dr. Stanford began his career as a Mechanical/Aerospace Engineer at Texas Instruments in 1982. In 1991, he pivoted into biomedical science and completed the physician-scientist training program (MD/PhD) at UCLA in 1998 and internal medicine residency at UCLA in 2001. Dr. Stanford was one of the pioneers in the field of hospital medicine. In 2002, he founded and led a 25-physician group of private practice hospitalists at Cedars-Sinai Medical Center in Los Angeles and was elected by his peers to be Clinical Chief of General Internal Medicine. He completed Professional Certification in Genetics and Genomics through Stanford University in 2018 and subsequently founded the Beverly Hills Institute for Precision Medicine.


Genomic Profiling Showcase:
Beverly Hills Institute for Precision Medicine

BHIPM provides comprehensive consultative services to primary care providers and their patients for the purposes of integrating precision medicine recommendations into primary care plans.

Precision Medicine Consultation in Primary Care
This presentation provides an overview of the consultative approach taken by BHIPM in using whole genome sequencing and analysis, alongside the patient's comprehensive past medical history, extended family medical history and recent biochemical studies to inform personalized primary care plans.

 Speaker Profile

Ph.D., Vice President, Data Science, Engineering, and Operations, ChromaCode, Inc.

Biography
Chris is an experienced engineer and manager in the life sciences industry focused on data science, product engineering, and process development. Most recently, he was an engineering manager at Illumina, leading the development of processes for consumables manufacturing across several major platforms, including the HiSeqX nanopatterned flowcell which enabled the $1000 genome.


Genomic Profiling Showcase:
ChromaCode, Inc.

ChromaCode is a software and reagent technology company with a focus on bioinformatics aimed at pioneering advancements in precision diagnostics by integrating reliable biochemical techniques with computational mathematics to enhance performance in testing, at a very low cost.

HDPCR™: Multiplexing Multiplied
ChromaCode expands utility of multiplexed PCR in genomic applications for NIPT and oncology through a unique combination of chemistry and data science. HDPCR™ yields 20-plex in a single well on qPCR and offers exponential utility on digital PCR platforms.

 Speaker Profile

Ph.D., Co-founder and CEO, Gencove Inc.

Biography
Joseph Pickrell is the co-founder and CEO of Gencove. With the vision of providing accessible and affordable genomic information, Gencove developed a novel low-pass whole genome sequencing and computational analysis platform for breakthrough biological discovery. Prior to starting Gencove, Dr. Pickrell was a Principal Investigator at the New York Genome Center (NYGC) and Adjunct Assistant Professor in the Department of Biological Sciences at Columbia University. At NYGC, the Pickrell Lab developed novel statistical approaches to transform large-scale genomic data into an improved understanding of human biology and history by understanding natural human variation and molecular and phenotypic consequences. Dr. Pickrell has a Ph.D. in human genetics from the University of Chicago and a B.S. in biology from the University of North Carolina-Chapel Hill. His work has been featured in the New York Times, the Wall Street Journal and has been published in prestigious scientific journals.


Genomic Profiling Showcase:
Gencove

Gencove is making genomic information ubiquitous through high-volume, cost-sensitive whole genome sequencing and computational analysis software. The Gencove platform provides academic, agriculture, biotech, and pharmaceutical companies genomic insights to impact health and sustainability.

Democratizing Genome Sequencing Through Software
Gencove developed high-throughput, cost-effective, low-pass whole genome sequencing with the potential to connect genomic information to phenotypic outcomes. Dr. Joe Pickrell will describe the Gencove technology platform and show how biotech and pharmaceutical companies are using the platform’s genomic insights.

 Speaker Profile

Ph.D., CSO, Clear Labs

Biography
As Chief Scientific Officer for Clear Labs, I lead the vision and strategy for talented teams of dedicated scientists who make life healthier through the application of genomics and intelligent analytics. From a leadership perspective, I prioritize team culture and empower my team members to maximize their talents and push the bounds of what’s possible. As a scientist and researcher, I have deep insights into the world of health, biotechnology, and next-generation sequencing, and I continue to contribute to the world of academia as an adjunct faculty member at Rutgers University. I want to leave a legacy by raising the quality of life and health of the world’s population. Through my work at Clear Labs, we have made a huge impact on food safety. I aim to expand that impact by using my skills to improve clinical and pharmaceutical genomics and their effectiveness in public health.